What Ligand Pharmaceuticals Incorporated's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 24 | 131 |
| Total trades | 33 | 205 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 43,119 | 220,318 |
| Disposed | 55,094 | 194,317 |
| Net activity | −11,975 | +26,001 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −17 | $307.74 | −$5.23K | 31,854 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −235 | $307.19 | −$72.2K | 31,871 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −404 | $306.18 | −$124K | 32,106 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −1,535 | $304.52 | −$467K | 32,510 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −1,976 | $303.54 | −$600K | 34,045 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Disclosed 10b5-1 sale · S | −833 | $302.51 | −$252K | 36,021 |
| Reardon Andrew | CLO & Secretary | Oct 02 | Exercise / conversion · M | +340 | $52.27 | +$17.8K | 36,854 |
| Zimmermann Martine | Director | Sep 22 | Withheld — tax / exercise cost · F | −115 | $298.50 | −$34.3K | 3,782 |
| Zimmermann Martine | Director | Sep 10 | Open-market sale · S | −1,200 | $285.00 | −$342K | 3,897 |
| Reardon Andrew | CLO & Secretary | Sep 03 | Disclosed 10b5-1 sale · S | −400 | $288.98 | −$116K | 36,514 |
| Reardon Andrew | CLO & Secretary | Sep 03 | Disclosed 10b5-1 sale · S | −385 | $287.53 | −$111K | 36,914 |
| Reardon Andrew | CLO & Secretary | Sep 03 | Disclosed 10b5-1 sale · S | −2,115 | $286.36 | −$606K | 37,299 |
| Reardon Andrew | CLO & Secretary | Sep 03 | Disclosed 10b5-1 sale · S | −1,800 | $285.17 | −$513K | 39,414 |
| Reardon Andrew | CLO & Secretary | Sep 03 | Disclosed 10b5-1 sale · S | −300 | $283.99 | −$85.2K | 41,214 |
| Haas Jason | Director | Aug 12 | Open-market sale · S | −7,138 | $292.81 | −$2.09M | 3,981 |
| Haas Jason | Director | Aug 12 | Exercise / conversion · M | +6,138 | $51.56 | +$316K | 11,119 |
| Espinoza Octavio | Chief Financial Officer | Aug 12 | Disclosed 10b5-1 sale · S | −31,641 | $292.07 | −$9.24M | 27,696 |
| Espinoza Octavio | Chief Financial Officer | Aug 12 | Exercise / conversion · M | +3,348 | $68.74 | +$230K | 59,337 |
| Espinoza Octavio | Chief Financial Officer | Aug 12 | Exercise / conversion · M | +7,171 | $57.22 | +$410K | 55,989 |
| Espinoza Octavio | Chief Financial Officer | Aug 12 | Exercise / conversion · M | +2,869 | $55.75 | +$160K | 48,818 |
Loading...
